Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of peripheral vascular disease using umbilical cord tissue-derived cells

A peripheral vascular disease and cell technology, applied in cardiovascular system diseases, muscular system diseases, neuromuscular system diseases, etc., can solve the problems of cell population heterogeneity, stem cells cannot be obtained, and have not yet been characterized

Inactive Publication Date: 2014-06-25
DEPUY SYNTHES PROD INC
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The limitations of obtaining stem cells from these methods are the inability to obtain sufficient volumes of cord blood or sufficient numbers of cells, and the fact that cell populations obtained from these sources are heterogeneous or have not been characterized

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
  • Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
  • Treatment of peripheral vascular disease using umbilical cord tissue-derived cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0168] Efficacy of umbilicus-derived cells in a mouse hindlimb peripheral ischemia model

[0169] Materials and methods

[0170] Culture and isolation of umbilical cord cells. Umbilicus-derived cells (UDCs) were prepared as described in US Patent Publication 2005 / 0058631 or 2005 / 0054098. Cells were cultured for 10 or 11 passages (approximately 20 to 25 population doublings) and then cryopreserved.

[0171] Ischemia model treatment group :

[0172] group

[0173] 1 PBS, negative control

[0174] 2 Expression plasmid of vascular endothelial growth factor (pVEGF), positive control

[0175] 3 cells of cell line #1, totaling 5 x 10 5 cells

[0176] 4 cells of cell line #1, totaling 1 x 10 6 cells

[0177] 5 cells of cell line #2, totaling 1 x 10 6 cells

[0178] 6 cultured cells of cell line #1, totaling 1 × 10 6 cells

[0179] Cell line 1: U120304p10

[0180] Cell line 2: U072804A p11

[0181] Sample preparation for injection. Cells were either thawed immedia...

example 2

[0195] Endothelial network formation assay

[0196] Angiogenesis, or the formation of new blood vessels, is necessary for the growth of new tissue. Induction of angiogenesis is an important therapeutic goal in many pathological conditions. For the identification of the potential angiogenic activity of umbilical cord tissue-derived cells in in vitro assays, an established method involves seeding endothelial cells onto a substrate coated with a biological cell culture (trade name MATRIGEL (BD Discovery Labware, Bedford, MA) ), and then extract the basement membrane (Nicosia and Ottinetti (1990) In Vitro Cell Dev. Biol. 26(2):119-28). Treatment of endothelial cells with angiogenic factors on MATRIGEL (BD Discovery Labware, Bedford, MA) stimulates the cells to form a network resembling capillaries. This is a commonly used in vitro assay for testing stimulators and inhibitors of angiogenesis (Ito et al. (1996) Int. J. Cancer 67(1):148-52). This experiment used a co-culture sys...

example 3

[0220] Effects of hUTC on proliferation and migration of endothelial cells in vitro

[0221] The study was conducted to determine the effect of human umbilical tissue-derived cells (hUTC) on endothelial cell proliferation and migration in vitro. These effects were examined by co-culturing hUTC and endothelial cells and by incubating human umbilical vein endothelial cell (HUVEC) cultures with hUTC lysates. The results showed that hUTC induces an increase in endothelial cell proliferation and migration. Furthermore, data suggest that these effects are mediated in part by fibroblast growth factor (FGF) and hepatocyte growth factor (HGF).

[0222] Materials and methods

[0223] cell culture

[0224] Cryopreserved human umbilical tissue-derived cells (hUTC) Lot No. 120304 were thawed at passages 8-9 and seeded on gelatin-coated bottles and cultured in Hayflick growth medium (low glucose DMEM (Gibco, cat. no. 11885-084), 15% v / v fetal bovine serum (FBS, Hyclone, catalog num...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.

Description

[0001] Cross References to Related Applications [0002] This application is a continuation-in-part of U.S. Patent Application 11 / 617,346, filed December 28, 2006, which claims the benefit of U.S. Provisional Patent Application 60 / 754,366, filed December 28, 2005, the content of which is Incorporated herein by reference in its entirety. technical field [0003] The present invention relates to the field of cell-based or regenerative therapies for patients with peripheral vascular disease, especially those suffering from peripheral ischemia. Specifically, the present invention provides cells derived from umbilical cord tissue that have the ability to stimulate and support angiogenesis, improve blood flow, regenerate, repair and ameliorate skeletal muscle damage caused by peripheral ischemic events, and protect skeletal muscle from Capacity for ischemic injury. Background technique [0004] Throughout this specification, various publications are cited, including patents, pub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/44A61K38/36A61P9/10
CPCA61K35/44A61K38/36A61P9/08A61P9/10A61P9/14A61P21/00
Inventor C.S.布恩苏塞索A.J.基姆S.德哈纳拉R.阿拉斯I.努尔R.梅德勒L.巴尔
Owner DEPUY SYNTHES PROD INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com